Related Experiment Video
Updated: Jan 27, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Abrupt visual loss during anti-vascular endothelial growth factor treatment for type 3 neovascularization
Jae Hui Kim1, Young Suk Chang2, Jong Woo Kim1
1Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul 150-034, Korea.
Aim:
To investigate the incidence of abrupt visual loss and its associated factors, during anti-vascular endothelial growth factor (VEGF) treatment for type 3 neovascularization.
Methods:
This retrospective study included 137 eyes that were newly diagnosed with type 3 neovascularization. All eyes were treated with anti-VEGF therapy. Abrupt visual loss was defined as loss of 5 or more lines in best-corrected visual acuity (BCVA) in comparison to the previous visit. The incidence and timing of abrupt visual loss as well as the factors associated with it, were determined. In addition, the BCVA at the final follow-up was compared between the eyes with and those without abrupt visual loss.
Results:
The mean follow-up period was 42.4±18.9mo after diagnosis, and abrupt visual loss was noted in 22 eyes (16.1%) at a mean of 19.6±13.9mo. Abrupt visual loss was found to be associated with subretinal hemorrhage in 11 eyes (50.0%), development of or increase in the height of pigment epithelial detachment with fluid in 8 eyes (36.4%), and tears in the retinal pigment epithelium in 3 eyes (13.6%). The logarithm of minimum angle of resolution (logMAR) mean BCVA at the final follow-up was 2.07±0.67 (Snellen equivalents: 20/2349) and 1.00±0.55 (20/200) in eyes with and without abrupt visual loss, respectively. BCVA was significantly worse in the eyes with abrupt visual loss (P<0.001).
Conclusion:
Abrupt visual loss is noted in 16.1% of patients with type 3 neovascularization and is associated with poor visual outcome. Additional studies are needed to determine how abrupt visual loss can be prevented.
Insights
Abrupt visual loss affects 16.1% of patients receiving anti-vascular endothelial growth factor (VEGF) therapy for type 3 neovascularization, leading to significantly worse visual outcomes.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Neovascularization
Background:
- Type 3 neovascularization is a significant cause of vision loss.
- Anti-vascular endothelial growth factor (VEGF) therapy is a common treatment for neovascular eye conditions.
- Abrupt visual loss is a potential complication during anti-VEGF treatment.
Purpose of the Study:
- To determine the incidence of abrupt visual loss in patients with type 3 neovascularization undergoing anti-VEGF treatment.
- To identify factors associated with abrupt visual loss.
- To compare visual acuity outcomes between patients with and without abrupt visual loss.
Main Methods:
- Retrospective study of 137 eyes with newly diagnosed type 3 neovascularization treated with anti-VEGF therapy.
- Abrupt visual loss defined as a loss of 5 or more lines of best-corrected visual acuity (BCVA).
- Analysis of incidence, timing, associated factors, and final BCVA.
Main Results:
- Abrupt visual loss occurred in 16.1% of eyes at a mean of 19.6 months post-diagnosis.
- Associated factors included subretinal hemorrhage (50.0%), pigment epithelial detachment with fluid (36.4%), and retinal pigment epithelium tears (13.6%).
- Eyes with abrupt visual loss had significantly worse final BCVA (logMAR 2.07) compared to those without (logMAR 1.00).
Conclusions:
- Abrupt visual loss is a significant complication in 16.1% of type 3 neovascularization patients treated with anti-VEGF therapy.
- This complication is linked to poor visual outcomes.
- Further research is required to develop preventative strategies for abrupt visual loss.
More Related Videos
05:56Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts
Published on: January 22, 2020
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity
Types of Step-Growth Polymers: Polyesters
Polyesters are commonly prepared from terephthalic acid and ethylene glycol; the crude product is known as poly(ethylene terephthalate) or PET. However, polyesters are synthesized industrially by transesterification of dimethyl terephthalate with ethylene glycol at 150 °C. The two reactants and the polymer...
Accessory Structures of the Skin: Hair Growth and Types